Skip to main content
. Author manuscript; available in PMC: 2023 Jan 14.
Published in final edited form as: Br J Haematol. 2022 Aug 27;200(2):137–149. doi: 10.1111/bjh.18418

Fig.2. Map of clinically documented BTK mutations.

Fig.2.

A) 3D mapping of common BTK missense mutations associated with resistance to multiple BTK inhibitors (previously published in Sharma et al, PMID: 27626698). B) Clinically reported BTK mutations in patients treated with ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib. Note that not all mapped mutations have been functionally validated. PH, pleckstrin homology domain; TH, Tec homology domain; SH, Src homology domain; Tyrosine kinase, tyrosine kinase domain. The height of the vertical bars represents the relevant abundance of the particular variants. *Experimentally predicted to be resistant to multiple BTK inhibitors. The graph was generated with BioRender.